Редактирование: SLCO1B1

Solute carrier organic anion transporter family member 1B1 (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Sodium-independent organic anion-transporting polypeptide 2) (OATP-2) (Solute carrier family 21 member 6) [LST1] [OATP1B1] [OATP2] [OATPC] [SLC21A6]

==Publications==

{{medline-entry
|title=The [[SLCO1B1]] c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/24263182
|abstract=The [[SLCO1B1]] c.521T>C polymorphism is associated with statin plasma levels and simvastatin-induced adverse drug reactions. We studied whether the c.521T>C polymorphism is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy, because these events are indicators of adverse drug reactions. We identified 1939 incident simvastatin and atorvastatin users in the Rotterdam Study, a population-based cohort study. Associations were studied using Cox proportional hazards analysis. Meta-analysis was performed with data from the Utrecht Cardiovascular Pharmacogenetics study. Simvastatin users with the c.521 CC genotype had a significantly higher risk of a dose decrease or switch than users with the TT genotype [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.05-2.88]. Female sex, age below 70 years, and low starting dose were risk factors. In atorvastatin users with starting dose of more than 20 mg, the risk of a dose decrease or switch was higher in users carrying a C allele than in users with the TT genotype (HR 3.26, 95% CI 1.47-7.25). In the meta-analysis the association in simvastatin users remained, with a significantly higher risk of a dose decrease or switch in simvastatin users with two minor alleles (HR 1.69, 95% CI 1.05-2.73). For atorvastatin users no significant association was found. In simvastatin users in the Rotterdam Study, we demonstrated an association between the c.521T>C polymorphism and dose decrease or switching, as indicators of adverse drug reactions, and provided risk factors for this association. For atorvastatin, an association was found in users with a starting dose of more than 20 mg.
|mesh-terms=* Aged
* Aging
* Anticholesteremic Agents
* Atorvastatin
* Cholesterol
* Cytosine
* Databases, Factual
* Dose-Response Relationship, Drug
* Female
* Genetic Association Studies
* Heptanoic Acids
* Humans
* Hypercholesterolemia
* Liver-Specific Organic Anion Transporter 1
* Male
* Middle Aged
* Organic Anion Transporters
* Polymorphism, Single Nucleotide
* Prospective Studies
* Pyrroles
* Risk Factors
* Sex Characteristics
* Simvastatin
* Thymine

|full-text-url=https://sci-hub.do/10.1097/FPC.0000000000000018
}}